Please use this identifier to cite or link to this item:
Title: SEOM clinical guideline for treatment of kidney cancer (2017)
Author: Gallardo, Enrique
Méndez-Vidal, María José
Perez-Gracia, Jose Luis
Sepúlveda-Sánchez, Juan Manuel
Campayo Guillaumes, Marc
Chirivella González, Isabel
García del Muro Solans, Xavier
González del Alba, Aránzazu
Grande, Enrique
Suarez, Cristina
Keywords: Càncer
Tractament adjuvant del càncer
Adjuvant treatment of cancer
Issue Date: 1-Jan-2018
Publisher: Springer Verlag
Abstract: The goal of this article is to provide recommendations about the management of kidney cancer. Based on pathologic and molecular features, several kidney cancer variants were described. Nephron-sparing techniques are the gold standard of localized disease. After a randomized trial, sunitinib could be considered in adjuvant treatment in high-risk patients. Patients with advanced disease constitute a heterogeneous population. Prognostic classification should be considered. Both sunitinib and pazopanib are the standard options for first-line systemic therapy in advanced renal cell carcinoma. Based on the results of two randomized trials, both nivolumab and cabozantinib should be considered the standard for second and further lines of therapy. Response evaluation for present therapies is a challenge.
Note: Reproducció del document publicat a:
It is part of: Clinical & Translational Oncology, 2018, vol. 20, p. 47-56
Related resource:
ISSN: 1699-048X
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Medicina)
Articles publicats en revistes (Ciències Clíniques)

Files in This Item:
File Description SizeFormat 
680081.pdf283.32 kBAdobe PDFView/Open
680081_Cor.pdfCorrection333.35 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons